Business
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION
VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION\nCanada NewsWire\nMONTREAL, Jan. 5, 2022\n\n\n\nHesperco now available in approximately 300 stores under the Loblaws banners Clinical study yields encouraging results that hesperidin may help reduce COVID-19 associated symptoms MONTREAL, Jan. 5, 2022 /CNW/ - Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE:VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, announced today that Hesperco, its unique flavonoid formulation approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw's banners including Loblaws, Dominion, Zehrs, Fortinio's, Your Independent Grocer and Superstore. \n\"We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications\", said Steve Saviuk, CEO. \"We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.\"\nValeo entered into a collaboration and licensing agreement with Ingenew Pharma Inc. (\"Ingenew\"), www.ingenewpharma.com, in April 2020 for the development, manufacture and commercialization of Hesperco. INGENEW has developed proprietary knowhow regarding the use of Hesperidin in instances of coronavirus infection and entered into a collaborative partnership with the Montreal Heart Institute to perform a randomized, double-blind, placebo controlled clinical trial.&...